Immix Biopharma, Inc.
NASDAQIMMX short interest surges 25% in one week to 13.1% of float, highest since May, as stock rallies 11.6% amid positive CAR-T trial data and analyst coverage initiation.
Snapshot as of 21 Jun 2026
No long-form analysis yet for IMMX. Pulse alerts and the live data picture are available on ORTEX.
Open IMMX on ORTEX →Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for IMMX — free to start on ORTEX.
Sign up for free →Open IMMX on ORTEX